12:00 AM
 | 
Feb 23, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CB-183: Phase I started

Cubist began a single ascending-dose Phase I trial to evaluate oral CB-183, 315 in 40-60...

Read the full 55 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >